Etanercept

Research use only, not for human use.

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.

Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.

——

Etanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score.Animal Model:Six-week-old male Lewis rats (adjuvant-induced arthritis (AIA) model) Dosage:10 mg/kg Administration:S.c.; every 3 days for 3 weeks Result:Significantly decreased the mean arthritis scores; Significant decreased in radiological score at the end of the treatment period.

——

Apoptosis

TNF

TNF

——

——

185243-69-0

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years